Zelboraf (vemurafenib) — Medica
Central nervous system cancers
Preferred products
- Cotellic (cobimetinib)
Initial criteria
- used for ONE of the following: adjuvant treatment of pilocytic astrocytoma, pleomorphic xanthoastrocytoma, circumscribed ganglioglioma/neuroglioma/glioneuronal tumor, or pediatric diffuse high-grade glioma; OR recurrent or progressive high-grade glioma, circumscribed glioma, or glioblastoma; OR brain metastases due to melanoma
- BRAF V600 mutation-positive disease
- prescribed in combination with Cotellic (cobimetinib)
Approval duration
1 year